What Happened to CVS Health Stock (CVS)?

CVS Health (NYSE: CVS) has undergone a significant strategic evolution, moving beyond its traditional retail pharmacy roots to become a comprehensive health solutions provider. This transformation gained substantial momentum with its 2018 acquisition of health insurer Aetna for approximately $69 billion, signaling a clear intent to manage the entire patient journey.

The company further solidified its position in healthcare delivery through two major acquisitions in 2023. In March 2023, CVS Health completed its $8 billion acquisition of Signify Health, a home-health and technology services provider, expanding its presence in value-based care and in-home patient assessments. This was closely followed by the $10.6 billion acquisition of Oak Street Health, a network of value-based primary care centers for Medicare Advantage patients, which closed in May 2023. These deals were central to CVS's strategy to expand into direct care delivery, aiming to influence the overall cost of care and improve patient outcomes, particularly for seniors.

However, this expansion has not been without challenges. CVS Health's pharmacy benefit management (PBM) arm, CVS Caremark, has faced increasing scrutiny. In January 2026, a report from the House Judiciary Committee questioned CVS Health's PBM policies, alleging that the company may have used its market power to restrict independent pharmacies from accessing competing digital pharmacy hubs, potentially violating antitrust laws. Additionally, in March 2026, a civil RICO lawsuit was filed against CVS Health, alleging fraud in connection with PBM contracts. The company has refuted these claims, stating its PBM practices aim to make prescription drugs more affordable.

Financial performance has also been impacted by broader industry trends. In January 2026, CVS stock experienced a decline after the Centers for Medicare & Medicaid Services (CMS) announced a modest rate increase for 2027 Medicare Advantage plans, which was below investor expectations and affected other managed care providers as well. Despite these headwinds, CVS Health reported strong fourth-quarter and full-year 2025 results in February 2026, with total revenues reaching a record high of $402.1 billion for the full year.

Most recently, on May 6, 2026, CVS Health announced strong first-quarter 2026 results, with total revenues increasing to $100.4 billion, up 6.2% year-over-year, and adjusted EPS of $2.57. The company subsequently raised its full-year 2026 guidance for adjusted EPS to a range of $7.30 to $7.50, up from the previous $7.00 to $7.20. This positive performance was largely driven by its Health Care Benefits segment (Aetna) and Pharmacy & Consumer Wellness segments, despite a cautious outlook on rising cost trends. CVS Health continues to focus on integrating its diverse businesses to provide a connected, convenient, and cost-effective healthcare experience, while also expanding biosimilar adoption through its Caremark formularies to improve affordability.